History of ABVD alters the number of oocytes vitrified after in vitro maturation in fertility preservation candidates

Future Oncol. 2016 Jul;12(14):1713-9. doi: 10.2217/fon-2016-0009. Epub 2016 Mar 10.

Abstract

Aim: This retrospective case-control study aimed at analyzing the results of in vitro maturation (IVM) of oocytes, used for fertility preservation (FP), in patients with history of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) for classical Hodgkin lymphoma.

Patients & methods: A total of 22 candidates for FP, having received ABVD at least 2 years before IVM for FP were studied. IVM results were compared with those of 44 breast cancer patients, without history of chemotherapy, matched for ovarian reserve parameters.

Results: The number of cumulo-oocyte complexes recovered and the total number of matured oocytes vitrified was lower in patients having received AVBD (5.5 ± 4.8 vs 8.5 ± 4.4 oocytes; p = 0.03 and 3.5 ± 3.7 vs 6 ± 3.0 oocytes; p < 0.04, respectively).

Conclusion: In light of these results, FP should be discussed before ABVD.

Keywords: ABVD; Hodgkin lymphoma; fertility preservation.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bleomycin / adverse effects
  • Case-Control Studies
  • Dacarbazine / adverse effects
  • Doxorubicin / adverse effects
  • Female
  • Fertility Preservation*
  • Hodgkin Disease / drug therapy*
  • Humans
  • Oocytes / drug effects*
  • Retrospective Studies
  • Vinblastine / adverse effects
  • Vitrification
  • Young Adult

Substances

  • Bleomycin
  • Vinblastine
  • Dacarbazine
  • Doxorubicin

Supplementary concepts

  • ABVD protocol